Orexigen Therapeutics (OREX) Misses Q4 EPS by 4c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Piper Jaffray Cuts Price Target on Orexigen Therapeutics (OREX) to $5 Following 4Q Results
February 29, 2016 8:13 AM ESTPiper Jaffray maintained an Overweight rating on Orexigen Therapeutics (NASDAQ: OREX), and cut the price target to $5.00 (from $11.00), following the company's 4Q earnings report. US Contrave royalties of $2.6M, helped OREX end 2015 with $214M of cash, sufficient through profitability based on growing revenues. Orexigen reported 4Q15 revenues of $4.9M, including $2.6M in Contrave... More
UPDATE: RBC Capital Downgrades Orexigen Therapeutics (OREX) to Sector Perform
February 29, 2016 6:52 AM EST(Updated - February 29, 2016 8:24 AM EST)
RBC Capital downgraded Orexigen Therapeutics (NASDAQ: OREX) from Outperform to Sector Perform with a price target of $1.00 (from $5.00). Analyst Simos Simeonidis sees a tougher road for Contrave/ Mysimba.
"Despite the already significant decline in OREX shares, we are downgrading to Sector Perform on what we view as a bleak outlook for both the US... More
